Benjamin Kim

Partner at Playground Global · Stanford, United States

Invests in AI

AI is one of the sectors on Benjamin Kim's investor profile, next to Biotech & Pharma, at early-stage venture, Series A and Series B. The record holds 7 deals, including Outpace Bio, Infinimmune and Lassogen, Inc..

Email Investor

Email Investor

Credits to line up before an early-stage round

Benjamin Kim backs companies at early-stage venture, Series A and Series B. A few of the larger credit programs on AI Perks for teams at that point:

Portfolio on record

Portfolio companies

  • Outpace Bio
  • Infinimmune
  • Lassogen, Inc.
  • Atomic AI
  • Amber Bio
  • Manifold Bio
  • Insamo

Investment focus

Backs startups in
Artificial Intelligence, Biotech & Pharma
Rounds
Early-stage venture, Series A, Series B
Profile
Venture investor
Deals on record
7
Based in
Stanford, United States

Ready to pitch AI investors?

AI Perks profiles show public professional information only, so there are no contact details here. Continue to find investors, send your pitch and track the replies.

Email Investor

Email Investor

More AI investors on AI Perks

Browse all AI investors

Questions founders ask

Does Benjamin Kim invest in AI startups?
Yes. Artificial Intelligence is one of the sectors on Benjamin Kim's investor profile, together with Biotech & Pharma. The stages on record are early-stage venture, Series A and Series B.
Which companies has Benjamin Kim backed?
The record lists 7 deals, including Outpace Bio, Infinimmune, Lassogen, Inc., Atomic AI and Amber Bio. None of them has a perk listed on AI Perks yet.
What credits can a startup claim before pitching Benjamin Kim?
For a company raising an early-stage round, AI Perks lists credits such as MongoDB (up to $25,000), Redis (up to $10,000), Aiven (up to $100,000) and Azure OpenAI (up to $150,000), with each program's terms and how to apply.
Does AI Perks publish investor contact details?
No. AI Perks profiles show public professional information only: name, role, location, stages, sectors and the portfolio on record. To reach investors, continue with the Email Investor button below.Email Investor

Email Investor

Source: public professional information. Is this you? Request removal

Email Investor

Email Investor